Status:
ACTIVE_NOT_RECRUITING
Studies of White Blood Cells Derived From HHT Patients
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
British Heart Foundation
Conditions:
Telangiectasia, Hereditary Hemorrhagic
Eligibility:
All Genders
Brief Summary
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an inherited vascular disease that leads to the development of dilated and fragile blood vessels. The study go...
Detailed Description
HHT is a vascular condition but many of the genes that are mutated to cause HHT (endoglin, ALK-1 and SMAD4) are also expressed in white blood cells. In this study, investigators will take blood sample...
Eligibility Criteria
Inclusion
- Patients with HHT,
- HHT patients family members
Exclusion
- Unable to provide informed consent
Key Trial Info
Start Date :
April 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00230633
Start Date
April 1 2002
End Date
October 1 2026
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College Hammersmith Campus
London, United Kingdom, W12 0NN